Results 171 to 180 of about 622,843 (190)

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Gut microbiome shift in long COVID: impact of disease and montelukast treatment. [PDF]

J Glob Health
Camps-Massa P, Pérez-Mormeneu J, Guevara-Nuñez D, Saiz-Escobedo L, Calatayud L, González-Díaz A, Sanllorente A, Vicens-Zygmunt V, Santos S, Morros R, Salvador-González B, Domínguez MÁ, Martí S, E-SPERANZA study group.   +13 more
europepmc   +1 more source

Analysis of C4 Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 596-605, March 2025.
ABSTRACT Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, is being evaluated for the treatment of pruritus in primary biliary cholangitis (PBC). Diarrhea is commonly reported with this drug class as IBAT inhibition redirects bile acids (BA) to the colon.
Fernando Carreño, Rashmi Mehta, Andrea Ribeiro de Souza, Jon Collins, Brandon Swift   +4 more
wiley   +1 more source

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action. [PDF]

Clin Pharmacol Ther
Zitzmann C, Ribeiro RM, Marc A, Zhou XJ, Perelson AS.   +4 more
europepmc   +1 more source

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques. [PDF]

Blood Adv
Hayal TB, Abraham DM, Demirci S, Fan X, Zhou Y, Hyzy SL, Lin MI, Linde N, Engels T, Golomb J, Bonifacino A, Schifanella L, Hoffmann V, Brinster LR, Blair RV, Midkiff CC, Franchini G, Kaur A, Tisdale JF, Donahue RE, Hong SG, Wu C, Dunbar CE.   +22 more
europepmc   +1 more source

A de novo algorithm for allele reconstruction from Oxford nanopore amplicon reads, with application to CYP2D6. [PDF]

Bioinformatics
Brown SD, Dreolini L, Minor A, Mozel M, Wong N, Mar S, Lieu A, Khan M, Carlson A, Hrynchak M, Holt RA, Missirlis PI.   +11 more
europepmc   +1 more source

Medullary and C3-C4 propriospinal pathways underlying mammalian forelimb movement control. [PDF]

Proc Natl Acad Sci U S A
Jindal V, Grudny MM, Wesson DW, Vaillancourt DE, Vahdat S.   +4 more
europepmc   +1 more source

Comparing affective bias modification by first- and second-generation antidepressants in male rats using a translational behavioural task. [PDF]

Neuropsychopharmacology
Kamenish KA, Cahill EN, Robinson ESJ.
europepmc   +1 more source

Behavioural Characterisation and Pharmacological Validation of an Incisional Wound-Related Pain Model. [PDF]

Eur J Pain
Healy CR, Redmond MC, Hopkins M, Gethin G, Pandit A, Finn DP.   +5 more
europepmc   +1 more source

Pharmacology and Therapeutics

Lancet, The, 1882
exaly   +10 more sources